– Integrated cancer care professionals to address treatments, shortages, and operational advances driving improved outcomes –   Orlando, FL – October 23, 2023 – Physicians, nurses, pharmacists, and other important clinical and administrative team members, along with partnering pharmaceutical industry representatives from all over the world will gather in Orlando October 25-27 for the NCODA […]

Desmoid tumors are rare, locally aggressive soft tissue tumors1 Until October 1, 2023, desmoid tumors fell under an ICD-10-CM code (D48.1) covering a variety of connective and soft tissue tumors of “uncertain behavior”2 As of October 1, 2023, ICD-10-CM diagnosis codes are available for desmoid tumors2   On October 1, 2023, location-specific International Classification of […]

JUNE 13, 2023 The PAN Foundation today announced opposition to alternative funding programs, which jeopardize patient access to specialty medications and redirect finite charitable funds away from uninsured and underinsured patients. We urge Congress and the administration to learn about the growing use of alternative funding programs, understand their detrimental impact on patients, and evaluate options […]

May 22, 2023 at 4:04 PM EDT — For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom relief — — Approval based on the positive PIONEER trial, in which once-daily AYVAKIT achieved significant improvements in disease symptoms and […]

[CAZENOVIA, NY – April 27, 2023] – NCODA urges the Centers for Medicare & Medicaid Services (CMS) to immediately retract a portion of a Frequently Asked Questions (FAQ) that suggests that physician practices mailing medications would violate the federal prohibition on self-referral for ancillary services (Stark law). At present, the Public Health Emergency (PHE) that […]

[CAZENOVIA, NY – March 30, 2023] – NCODA University, a division of NCODA that provides top-tier education for future and present oncology pharmacists, has launched a new 15-hour Oncology Basics Course. This first-of-its-kind course will reinforce knowledge of the etiology and pathophysiology of cancer, provide a deeper understanding of commonly used anti-cancer drug classes, and […]

— First Trop-2 Directed ADC to Demonstrate Overall Survival Benefit in HR+/HER2- Metastatic Breast Cancer Patients who had Received Prior Endocrine-based Therapy and at Least Two Chemotherapies — — Trodelvy has Now Improved Survival in both Pre-Treated HR+/HER2- Metastatic Breast Cancer and in Second-Line Metastatic Triple-Negative Breast Cancer —   FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. […]

FOR IMMEDIATE RELEASE February 23, 2023 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629   NCODA APPOINTS THREE NEW MEMBERS TO ITS EXECUTIVE COUNCIL CAZENOVIA, NY – NCODA is delighted to announce the expansion of its Executive Council with the appointment of three appointed oncology healthcare leaders: Luis Campos, MD, John Marshall, MD, and Scott Freeswick, PharmD, […]

February 16, 2023 Fresenius Kabi’s first U.S. biosimilar launch Provides accessible, high-quality treatment option for U.S. cancer patients undergoing chemotherapy to reduce the incidence of infection as manifested by febrile neutropenia Strengthens Fresenius Kabi’s heritage in oncology and its commitment to oncology patients The expansion of the company’s global biosimilars portfolio focused on oncology and […]